产品
编 号：F757600
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 339986-90-2
产品详情
生物活性：
Tucotuzumab (Anti-EPCAM Recombinant Antibody) is an antigen-specific IgG1 monoclonal antibody that targets human epithelial cell adhesion molecule (EpCAM). Tucotuzumab links two IL-2 molecules and is an immunosuppressant and anti-tumor active molecule.
体内研究：
Tucotuzumab (75 μg; 瘤内注射; 每日 5 次，每次15 μg (总剂量 75 μg)，各用50 μL PBS; 在第 10 天和第 14 天)，肿瘤生长抑制显著增强，生存率提高。Animal Model:Female Balb/c mice bearing CT26-KS colon adenocarcinoma
Dosage:75 μg
Administration:Intratumoral injection; 5 daily of 15 μg (total dose of 75 μg), each in 50 μL PBS; on days 10 and 14
Result:Resulted in significantly greater tumor growth suppression and enhanced survival.
体外研究：
Tucotuzumab 靶向肿瘤并通过 IL-2 应答性免疫细胞刺激抗肿瘤免疫反应，以及通过其 Fc 受体刺激免疫细胞。
Tucotuzumab (Anti-EPCAM Recombinant Antibody) is an antigen-specific IgG1 monoclonal antibody that targets human epithelial cell adhesion molecule (EpCAM). Tucotuzumab links two IL-2 molecules and is an immunosuppressant and anti-tumor active molecule.
体内研究：
Tucotuzumab (75 μg; 瘤内注射; 每日 5 次，每次15 μg (总剂量 75 μg)，各用50 μL PBS; 在第 10 天和第 14 天)，肿瘤生长抑制显著增强，生存率提高。Animal Model:Female Balb/c mice bearing CT26-KS colon adenocarcinoma
Dosage:75 μg
Administration:Intratumoral injection; 5 daily of 15 μg (total dose of 75 μg), each in 50 μL PBS; on days 10 and 14
Result:Resulted in significantly greater tumor growth suppression and enhanced survival.
体外研究：
Tucotuzumab 靶向肿瘤并通过 IL-2 应答性免疫细胞刺激抗肿瘤免疫反应，以及通过其 Fc 受体刺激免疫细胞。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备